Skip to main content
. 2018 Sep 26;29(4):565–568. doi: 10.1007/s13337-018-0491-z

Fig. 1.

Fig. 1

Schematic representation of CPV ARMS-PCR strategy for differentiating vaccine (CPV-2) and field strains (CPV-2a/CPV-2b/CPV-2c) showing primer binding region and amplified product formed. The bold case (bigger font size) represents the target codon (position 259–261) and primer binding site. Deliberate mismatch of the nucleotide at − 2 from 3′ end position within primers is underlined